On Friday, Sanofi SA (ADR )(NYSE:SNY)’s shares inclined 0.13% to $53.44.
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals, Inc. declared that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to 3 (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
The Committee’s recommendation was based on Praluent’s benefit-risk profile, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show comprising, positive results in reducing LDL-C. Common adverse events that were more frequently stated in patients treated with Praluent than the control groups comprised of injection site reaction and pruritus (itching).
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
Agilent Technologies Inc (NYSE:A)’s shares dropped -2.34% to $39.31.
Agilent Technologies Inc. (A) declared that Dr. Lawrence J. Lesko has received an Agilent Thought Leader Award in support of his research into preclinical toxicological assessments of new medicines.
An internationally recognized pharmacologist, Dr. Lesko directs the Center for Pharmacometrics and Systems Pharmacology at the University of Florida’s College of Pharmacy in Orlando.
Agilent Technologies, Inc. provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications, and electronics industries worldwide. The company’s Life Sciences and Diagnostics segment offers liquid chromatography systems, columns, and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; nuclear magnetic resonance, magnetic resonance imaging, and X-ray diffraction systems; immunohistochemistry; in situ hybridization; hematoxylin and eosin staining; special staining, DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation and gene expression profiling; next generation sequencing target enrichment; and automated gel electrophoresis-based sample analysis systems.
At the end of Friday’s trade, Manitowoc Company Inc (NYSE:MTW)‘s shares dipped -2.70% to $17.10.
The Manitowoc Company, Inc. (MTW) declared that it will release its second-quarter 2015 financial results on Wednesday, July 29, after the close of market. The company’s second-quarter results will also be talk about by Manitowoc’s administration team during a live conference call for security analysts and institutional investors, which will be held at 10:00 a.m., Eastern Time, on Thursday, July 30.
The Manitowoc Company, Inc. designs, manufactures, and sells cranes and related products, and foodservice equipment worldwide. The Cranes and Related Products segment offers lattice-boom cranes, counting crawler and truck mounted lattice-boom cranes, and crawler crane attachments; tower cranes comprising top slewing, luffing jib, topless, and self-erecting tower cranes; mobile telescopic cranes, such as rough terrain, all-terrain, truck mounted, and industrial cranes; and boom trucks comprising telescopic boom trucks under the Manitowoc, Potain, Grove, National Crane, and Shuttlelift brands. Its products are used in various applications, counting energy and utilities; petrochemical and industrial projects; infrastructure development, such as road, bridge, and airport construction; and commercial and high-rise residential construction.
DealerTrack Technologies Inc (NASDAQ:TRAK), ended its Friday’s trading session with -0.27% loss, and closed at $61.98.
Dealertrack Technologies ( TRAK) received two Bronze Stevie® Awards at the recent 13th Annual American Business Awards in Chicago. Dealertrack received an award for its Digital Retailing Solution in the “Innovation of the Year - Business Products Industries” category, and the company’s Dealer.com Seamless Websites were honored in the “Automotive & Transport Equipment & Transportation” websites category.
The American Business Awards are the nation’s premier business awards program recognizing a broad spectrum of American business professionals and organizations – from non-profits, emerging start-ups, major public companies and government agencies to corner-office executives, corporate communicators, support staff and customer service teams. A second Stevie Awards ceremony will be held in San Francisco on September 11, 2015, honoring additional winners in the new product and technology-related categories. Dealertrack’s eMenu for iPad is a finalist in the “Integrated Mobile Experience” category, which is planned to be declared at the San Francisco ceremony.
Dealertrack Technologies, Inc. provides Web-based software solutions and services to the automotive retail industry in the United States and Canada. It offers digital marketing solutions, which provide Websites, digital advertising, and other digital marketing offerings to assist dealers in achieving higher lead conversion rates that assist to optimize various shoppers to their Websites; dealer administration solutions, which provide dealer administration system featuring tools and real-time data access; and F&I solutions that allow dealers to streamline the in-store and online sales, in addition to financing processes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
